18F-FDG and 18F-Fluorocholine PET as Prognostic Biomarkers in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Prospective Multicenter Study.

Key Points

• This study aims to assess the prognostic value of F-FDG PET and F-Fluorocholine PET in advanced hepatocellular carcinoma patients undergoing sorafenib treatment.
• Prospective multicenter design involving advanced hepatocellular carcinoma patients
• Evaluation of F-FDG and F-Fluorocholine PET/CT scans
• Comparative analysis of prognostic information provided by each imaging modality
• F-FCH PET/CT does not add prognostic value beyond current methods in this patient population.